CN1069542C - 一种治疗慢性肝病的药物及其制备方法 - Google Patents
一种治疗慢性肝病的药物及其制备方法 Download PDFInfo
- Publication number
- CN1069542C CN1069542C CN99113887A CN99113887A CN1069542C CN 1069542 C CN1069542 C CN 1069542C CN 99113887 A CN99113887 A CN 99113887A CN 99113887 A CN99113887 A CN 99113887A CN 1069542 C CN1069542 C CN 1069542C
- Authority
- CN
- China
- Prior art keywords
- medicine
- treatment
- starch
- radix salviae
- chronic hepatopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 230000001684 chronic effect Effects 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000000843 powder Substances 0.000 claims abstract description 17
- 208000019423 liver disease Diseases 0.000 claims abstract description 12
- 229920002472 Starch Polymers 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 235000019698 starch Nutrition 0.000 claims abstract description 11
- 239000008107 starch Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 241000190633 Cordyceps Species 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000002879 macerating effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 16
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 14
- 206010016654 Fibrosis Diseases 0.000 abstract description 9
- 208000002672 hepatitis B Diseases 0.000 abstract description 8
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract description 6
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000007882 cirrhosis Effects 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 244000144730 Amygdalus persica Species 0.000 abstract description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract description 2
- 235000011613 Pinus brutia Nutrition 0.000 abstract description 2
- 241000018646 Pinus brutia Species 0.000 abstract description 2
- 240000006079 Schisandra chinensis Species 0.000 abstract description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 240000008027 Akebia quinata Species 0.000 abstract 1
- 235000007756 Akebia quinata Nutrition 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 240000001307 Myosotis scorpioides Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 10
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 241000272525 Anas platyrhynchos Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 235000011609 Pinus massoniana Nutrition 0.000 description 2
- 241000018650 Pinus massoniana Species 0.000 description 2
- 235000011610 Pinus tabuliformis Nutrition 0.000 description 2
- 241000018651 Pinus tabuliformis Species 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- 241000169680 Aphloia theiformis Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000725618 Duck hepatitis B virus Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 235000015533 Prunus davidiana Nutrition 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- -1 aromatic amino acid Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229960004534 orgotein Drugs 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108010034596 procollagen Type III-N-terminal peptide Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别 | n | 肝蛋白(mg/g肝) | 肝Hyp(mg/g蛋白) |
正常对照组模型对照组秋水仙碱组本发明组 | 812129 | 242.8±32.1**182.6±46.2240.7±22.6***243.2±26.7*** | 0.46±0.16***1.28±0.420.57±0.18***0.59±0.07*** |
组别n | 平均直径(mm) | 平均面积mm2/个) | 平均体积(mm3/个) | 面积密度(mm2/cm2) | 体积密度(mm3/cm3) |
模型14周11对照组24周11本发明组14周1124周13 | 0.36±0.081.10±0.580.26±0.04**0.37±0.11*** | 0.14±0.072.48±3.090.07±0.02**0.32±0.43* | 0.007±0.0060.352±0.3400.002±0.001*0.014±0.008* | 19.63±18.7183.24±17.563.47±1.88**22.48±13.28*** | 24.14±28.51417.75±320.602.52±1.74*61.48±100.10 |
组别 n | 脂肪变性 | 胶原纤维 | MDA(nM/g肝) | S0D(NU/1%肝匀浆) |
模型组 12秋水仙碱组11本发明组 12 | 2.58±0.791.64±0.67**1.60±0.70** | 2.42±0.901.55±0.93*1.40±0.70*** | 329.2±67.9312.6±109.6273.8±48.2* | 837.6±209.2917.0±208.31105.8±142.0** |
药名 | 剂量(g/kg) | 实验批数 | 鸭数(只) | 鸭血清DHBV-DNA抑制率% | ||
T5 | T10 | P3 | ||||
本发明浸膏粉 | 粗 纯2.0 1.36Bid×10po. | ⅠⅡⅢ | 666 | 50.01**42.97*42.68* | 71.97**47.77*53.00** | 27.7136.6730.94 |
无环鸟苷 | 0.1g/kgBid×10po. | Ⅲ | 6 | 17.01 | 60.72** | 30.70 |
项目 | 正常人 | 慢乙肝 | 观 察 组 | 对 照 组 | ||||
治疗前 | 治疗后 | 治前-治后 | 治疗前 | 治疗后 | 治前-治后 | |||
MAO(u) | 28±13(20) | 63±29△(37) | 64±30 | 28±16** | 36±27▲(30) | 60±30 | 47±33 | 13±14(7) |
TIMP | 164±20(60) | 192±39△△(42) | 184±58 | 153±54** | 31±44▲(24) | 204±59 | 39±39*** | 65±47(18) |
P-Ⅲ-P | 0.31±0.12(15) | 1.41±2.19△(34) | 1.81±3.90 | 0.80±1.69* | 1.01±2.08(20) | 1.57±1.46 | 1.71±3.14 | -0.14±2.51(14) |
Ⅳ-C | 99±23(60) | 494±300△(46) | 547±345 | 386±212** | 161±262(29) | 404±179 | 333±150* | 72±121(17) |
HA | 38±36(60) | 371±295△(61) | 377±293 | 208±85*** | 167±199(44) | 356±313 | 220±218* | 136±251(17) |
LN(ng/ml) | 234±69(60) | 373±71△(61) | 369±73 | 210±241*** | 161±116▲(42) | 382±68 | 282±103*** | 99±92(18) |
尿Hyp(mg/24h) | 33.7±21.9(18) | 21.4±8.4△△ | 21.6±8.9 | 24.5±7.8* | 3.2±7.5(29) | 20.7±7.3 | 22.6±5.6 | 2.0±6.5(11) |
项目 | 正常人 | 肝硬化患者 | 观察组 对照组 | |||
治疗前 | 治疗后 | 治疗前 | 治疗后 | |||
T(pmol/L)E2/T尿17-KS(mg/24h) | 180±58(28)0.80±0.25(28)9.24±2.08(12) | 130±55**(40)1.50±1.02**(40)5.68±2.72*(40) | 133±61(12)1.44±1.11(12)5.48±2.99(16) | 188±78△(12)0.89±1.08△(12)7.56±4.79(16) | 12 7±58**(10)1.43±0.97**(10)6.01±2.57*(12) | 113±54(10)1.65±1.04(10)4.91±0.53(12) |
观测项目 | 正常人 | 观察组 对照组 | |||
治疗前 | 治疗后 | 治疗前 | 治疗后 | ||
HA(μg/L)LM(ng/L)尿Hyp(mg/24h) | 30±48(30)354±193(37)33.7±21.9(18) | 570±273*(19)504±163*(13)25.3±14.7(16) | 490±224△(19)429±113△(13)27.1±19.8(16) | 648±348*(18)538±149*(15)31.1±9.6(13) | 712±316(18)547±158(15)31.9±13.5(13) |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99113887A CN1069542C (zh) | 1999-07-19 | 1999-07-19 | 一种治疗慢性肝病的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99113887A CN1069542C (zh) | 1999-07-19 | 1999-07-19 | 一种治疗慢性肝病的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1243743A CN1243743A (zh) | 2000-02-09 |
CN1069542C true CN1069542C (zh) | 2001-08-15 |
Family
ID=5277030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99113887A Expired - Lifetime CN1069542C (zh) | 1999-07-19 | 1999-07-19 | 一种治疗慢性肝病的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1069542C (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1127917C (zh) * | 2000-10-09 | 2003-11-19 | 北京长寿保健品有限公司 | 一种延缓衰老的功能性营养保健品 |
CN100394946C (zh) * | 2004-12-17 | 2008-06-18 | 上海中医药大学 | 一种能改善肺纤维化的中药制剂 |
CN1839996A (zh) * | 2006-01-12 | 2006-10-04 | 上海现代中医药技术发展有限公司 | 一种治疗慢性肝病的中药复方制剂及其制备方法 |
CN1899415B (zh) * | 2006-01-12 | 2010-05-12 | 上海现代中医药技术发展有限公司 | 一种治疗慢性肝病的中药复方制剂及其制备方法 |
JP2008201749A (ja) * | 2007-02-21 | 2008-09-04 | Okayama Univ | 肝細胞増殖因子産生誘導剤及びその医薬品組成物 |
CN101334386B (zh) | 2007-04-27 | 2012-07-11 | 上海现代中医药股份有限公司 | 扶正化淤植物药血浆苦杏仁苷的测定方法 |
CN101042380A (zh) | 2007-04-27 | 2007-09-26 | 上海现代中医药技术发展有限公司 | 扶正化淤植物药血浆五味子乙素的测定方法 |
CN101078712A (zh) | 2007-04-27 | 2007-11-28 | 上海现代中医药技术发展有限公司 | 扶正化瘀植物药血浆丹参素和丹酚酸b的测定方法 |
CN101045092A (zh) * | 2007-04-29 | 2007-10-03 | 上海现代中医药技术发展有限公司 | 一种扶正化瘀植物药组合物的应用 |
CN103550547B (zh) * | 2013-10-25 | 2015-06-10 | 孙振玲 | 一种治疗肝炎后综合症的中药 |
CN109248229B (zh) * | 2018-10-16 | 2021-12-24 | 大连润生康泰医学检验实验室有限公司 | 一种预防和治疗免疫性肝损伤、药物性肝损伤的药物组合物及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1056423A (zh) * | 1990-05-11 | 1991-11-27 | 陈江辉 | 清肝宝口服液的配制方法 |
-
1999
- 1999-07-19 CN CN99113887A patent/CN1069542C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1056423A (zh) * | 1990-05-11 | 1991-11-27 | 陈江辉 | 清肝宝口服液的配制方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1243743A (zh) | 2000-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1286513C (zh) | 一种治疗皮肤病的中药组合物及其制备方法 | |
US6696094B2 (en) | Herbal pharmaceutical composition for treatment of HIV/AIDS patients | |
CN101181351B (zh) | 一种抗疲劳、增强免疫的中药组合物及其制备方法 | |
CN1069542C (zh) | 一种治疗慢性肝病的药物及其制备方法 | |
CN101933973B (zh) | 防治肝损伤的药物组合物 | |
CN1256133C (zh) | 一种抗疲劳的中药组合物及其制备方法 | |
CN101926861A (zh) | 用于增强非特异性免疫功能的中药兽用药的制备方法 | |
CN101342249B (zh) | 一种***的中药制剂及其制备方法 | |
CN1056755C (zh) | 一种治疗肝炎的药物 | |
KR20030055127A (ko) | 항고지혈증 조성물 | |
CN101912452A (zh) | 用于增强非特异性免疫功能的兽用中药组合物及其应用 | |
CN104771589A (zh) | 一种治疗脂肪肝的中药组合物及其应用 | |
CN103705578A (zh) | 具有降血脂与抑制血糖升高作用的中药制剂及其制备方法 | |
CN103690832A (zh) | 一种治疗病毒性心肌炎的中药组合物 | |
CN1202847C (zh) | 一种治疗糖尿病的药物 | |
KR20150106074A (ko) | 천마가미방을 포함하는 기억력 개선용 조성물 | |
CN1899574A (zh) | 一种防治肝癌的中药组合物及其应用 | |
CN1814176A (zh) | 一种治疗肺结核病的中药组合物与应用 | |
CN110237188A (zh) | 一种防治高血糖、高血脂的铁皮石斛复方颗粒剂 | |
CN1060051C (zh) | 一种抗癌组合物及其制备方法 | |
CN1394614A (zh) | 一种具有调节血脂作用的保健品及制备方法 | |
CN109172756B (zh) | 一种治疗肝病的中药组合物 | |
CN1814250A (zh) | 一种防治肝硬化腹水的中药组合物及其应用 | |
CN101700323B (zh) | 一种防治肝癌的药物组合物 | |
CN1291729C (zh) | 贯叶金丝桃抗病毒中药制剂及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONGYIYAO COLLEGE, SHANGHAI CITY Free format text: FORMER OWNER: SHANGHAI UNIV. OF TRADITIONAL CHINESE MEDICINE Effective date: 20021011 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20021011 Patentee after: Shanghai University of Traditional Chinese Medicine technology services Patentee before: Shanghai University of Traditional Chinese Medicine |
|
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI HYUNDAI CHINASE MEDICAL TECHNOLOGY DEVEL Free format text: FORMER OWNER: ZHONGYIYAO COLLEGE, SHANGHAI CITY Effective date: 20021227 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20021227 Address after: 200051 days in Shanghai City Road 600 Lane 4, building 7F-C, Sichuan Patentee after: Shanghai Modern Chinese Traditional Medicine Technology Development Co., Ltd. Address before: 200032 No. 530, Lingling Road, Shanghai Patentee before: Shanghai University of Traditional Chinese Medicine technology services |
|
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI HUANG HAI PHARMACEUTICAL CO. LTD. Free format text: FORMER OWNER: SHANGHAI HYUNDAI CHINASE MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20080829 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080829 Address after: Shanghai City, Baoshan District Sheng Qiao Zhen Shi Tai Road No. 1288 Patentee after: Shanghai Huanghai Pharmaceutical Co., Ltd. Address before: Shanghai City Days Road 600 Lane 4, building 7F-C, Sichuan Patentee before: Shanghai Modern Chinese Traditional Medicine Technology Development Co., Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20010815 |